China Orders All Injectables Inspected In Wake Of Three Deaths
This article was originally published in PharmAsia News
Executive Summary
China's State FDA ordered its local bureaus around the country to inspect all intravenous injectables by the end of the year to ensure none is contaminated. The agency took the action in the wake of at least three incidents in which people died after receiving an injection with an herb produced by Wandashan Pharmaceutical, later found to be contaminated with bacteria. SFDA bureaus were instructed to determine how an injection was produced, its ingredients, equipment used and other information through quality spot-checks and risk evaluation. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.